Literature DB >> 15701926

Interleukin-6 and C-reactive protein in metastatic renal cell carcinoma.

Ozden Altundag, Kadri Altundag, Esra Gunduz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15701926     DOI： 10.1200/JCO.2005.05.155

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  17 in total

Review 1.  Targeting the IL-6/JAK/STAT3 signalling axis in cancer.

Authors:  Daniel E Johnson; Rachel A O'Keefe; Jennifer R Grandis
Journal:  Nat Rev Clin Oncol       Date:  2018-02-06       Impact factor: 66.675

2.  FAK promotes stromal PD-L2 expression associated with poor survival in pancreatic cancer.

Authors:  David Taggart; Andrew H Sims; Catherine Davidson; David W Lonergan; Marta Canel; Alan Serrels
Journal:  Br J Cancer       Date:  2022-09-22       Impact factor: 9.075

Review 3.  Mechanistic Biomarkers Informative of Both Cancer and Cardiovascular Disease: JACC State-of-the-Art Review.

Authors:  Vivek Narayan; Elizabeth W Thompson; Biniyam Demissei; Jennifer E Ho; James L Januzzi; Bonnie Ky
Journal:  J Am Coll Cardiol       Date:  2020-06-02       Impact factor: 24.094

4.  A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer.

Authors:  J-F Rossi; S Négrier; N D James; I Kocak; R Hawkins; H Davis; U Prabhakar; X Qin; P Mulders; B Berns
Journal:  Br J Cancer       Date:  2010-08-31       Impact factor: 7.640

Review 5.  Role of interleukin-6 in cancer progression and therapeutic resistance.

Authors:  Neeraj Kumari; B S Dwarakanath; Asmita Das; Anant Narayan Bhatt
Journal:  Tumour Biol       Date:  2016-06-03

Review 6.  Interplay between inflammatory tumor microenvironment and cancer stem cells.

Authors:  Shijian Zhang; Xi Yang; Lei Wang; Chenping Zhang
Journal:  Oncol Lett       Date:  2018-05-16       Impact factor: 2.967

7.  The ketogenic diet is not feasible as a therapy in a CD-1 nu/nu mouse model of renal cell carcinoma with features of Stauffer's syndrome.

Authors:  Silvia Vidali; Sepideh Aminzadeh-Gohari; René Günther Feichtinger; Renaud Vatrinet; Andreas Koller; Felix Locker; Tricia Rutherford; Maura O'Donnell; Andrea Stöger-Kleiber; Bridget Lambert; Thomas Klaus Felder; Wolfgang Sperl; Barbara Kofler
Journal:  Oncotarget       Date:  2017-07-17

8.  Angiogenic, inflammatory and immunologic markers in predicting response to sunitinib in metastatic renal cell carcinoma.

Authors:  Ryuichi Mizuno; Go Kimura; Satoshi Fukasawa; Takeshi Ueda; Tsunenori Kondo; Hidehiko Hara; Sunao Shoji; Kent Kanao; Hayakazu Nakazawa; Kazunari Tanabe; Shigeo Horie; Mototsugu Oya
Journal:  Cancer Sci       Date:  2017-08-20       Impact factor: 6.716

Review 9.  Tumor-related interleukins: old validated targets for new anti-cancer drug development.

Authors:  Sarra Setrerrahmane; Hanmei Xu
Journal:  Mol Cancer       Date:  2017-09-19       Impact factor: 27.401

Review 10.  Systematic literature review of IL-6 as a biomarker or treatment target in patients with gastric, bile duct, pancreatic and colorectal cancer.

Authors:  Noomi Vainer; Christian Dehlendorff; Julia S Johansen
Journal:  Oncotarget       Date:  2018-07-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.